Exicure (NASDAQ:XCUR) Announces Earnings Results, Beats Estimates By $18.42 EPS

Exicure (NASDAQ:XCUR) announced its quarterly earnings data on Friday. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($18.60) by $18.42, FiscalAI reports.

Exicure Stock Performance

Shares of XCUR stock opened at $1.25 on Friday. The company has a market capitalization of $7.96 million, a P/E ratio of -0.95 and a beta of 3.65. Exicure has a 52 week low of $1.18 and a 52 week high of $9.48. The company’s 50 day moving average price is $1.96 and its two-hundred day moving average price is $3.14.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Exicure from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has a consensus rating of “Sell”.

Exicure Company Profile

Exicure is a clinical‐stage biotechnology company pioneering the development of next‐generation genetic medicines through its proprietary spherical nucleic acid (SNA) delivery platform. This nanotechnology‐based approach is designed to facilitate the intracellular delivery of oligonucleotide therapeutics, addressing longstanding challenges in targeting hard‐to‐reach tissues such as the central nervous system.

The company’s pipeline encompasses programs for neurological disorders—including Huntington’s disease, Parkinson’s disease and Alzheimer’s disease—as well as exploratory efforts in dermatological indications and oncology.